Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Fong

Showing results (61-70 of 198) with videos related to

Pageof 20
Sort By:
The Journal of Clinical Investigation|July 16, 2009
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humansYafei Hou, Jason DeVoss, Vinh Dao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2012
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patientsSerena S Kwek, Vinh Dao, Ritu Roy, et al.
Cancer Immunology, Immunotherapy : CII|January 9, 2021
Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patientsElliot Naidus, Jerome Bouquet, David Y Oh, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2010
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseBrian M Olson, Thomas P Frye, Laura E Johnson, et al.
Blood|June 5, 2008
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashionBrian Kavanagh, Shaun O'Brien, David Lee, et al.
Clinical Genitourinary Cancer|January 21, 2018
Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T ImmunotherapyXiao X Wei, Jaselle Perry, Emily Chang, et al.
JCO Precision Oncology|February 1, 2022
Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine CarcinomaJulia Whitman, Adel Kardosh, Luis Diaz, et al.
BJU International|June 27, 2006
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapyAmy M Lin, Brian I Rini, Vivian Weinberg, et al.
Cancer Research|November 25, 2010
Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patientsFelix Moltzahn, Adam B Olshen, Lauren Baehner, et al.
Pediatrics|August 9, 2017
Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled TrialMichael D Cabana, Michelle McKean, Aaron B Caughey, et al.
Pageof 20

Showing results (61-70 of 198) with videos related to

Sort By:
Pageof 20
The Journal of Clinical Investigation|July 16, 2009
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humansYafei Hou, Jason DeVoss, Vinh Dao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2012
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patientsSerena S Kwek, Vinh Dao, Ritu Roy, et al.
Cancer Immunology, Immunotherapy : CII|January 9, 2021
Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patientsElliot Naidus, Jerome Bouquet, David Y Oh, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2010
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseBrian M Olson, Thomas P Frye, Laura E Johnson, et al.
Blood|June 5, 2008
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashionBrian Kavanagh, Shaun O'Brien, David Lee, et al.
Clinical Genitourinary Cancer|January 21, 2018
Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T ImmunotherapyXiao X Wei, Jaselle Perry, Emily Chang, et al.
JCO Precision Oncology|February 1, 2022
Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine CarcinomaJulia Whitman, Adel Kardosh, Luis Diaz, et al.
BJU International|June 27, 2006
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapyAmy M Lin, Brian I Rini, Vivian Weinberg, et al.
Cancer Research|November 25, 2010
Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patientsFelix Moltzahn, Adam B Olshen, Lauren Baehner, et al.
Pediatrics|August 9, 2017
Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled TrialMichael D Cabana, Michelle McKean, Aaron B Caughey, et al.
Pageof 20